On Friday, Piper Sandler reaffirmed its Overweight rating on shares of Sutro Biopharma (NASDAQ:STRO) with a steady price target of $11.00. The firm's analysis highlights Sutro's progress in developing advanced antibody-drug conjugates (ADCs), particularly noting the potential of luveltamab tazevibulin (FolRa), which is currently undergoing the pivotal REFRaME-O1 trial.
Positive interim results from this trial on overall response rate (ORR) and duration of response (DoR) could pave the way for an accelerated approval process.
Sutro Biopharma has a strategic plan to file three Investigational New Drug (IND) applications over the coming three years. This includes the tissue factor ADC STRO-004 slated for the second half of 2025, a higher DAR ADC in 2026, and the introduction of the first dual-payload ADC in 2027. These developments are part of the company's commitment to expanding its pipeline of next-generation therapeutic options.
The company has also entered into a lucrative partnership with Ipsen concerning the ROR1 ADC STRO-003, securing a $75 million upfront payment. This deal could potentially yield up to $824 million in milestone payments, in addition to royalties. Such partnerships are indicative of the industry's confidence in Sutro's ADC technology and its therapeutic potential.
Furthermore, Sutro has an ongoing collaboration with Astellas, focusing on the development of two immunostimulatory ADCs (iADCs). These iADCs are designed to deliver both cytotoxic and immunostimulatory payloads, a novel approach in the treatment of cancer.
Piper Sandler's reiterated Overweight rating and $11 price target reflect the firm's positive outlook on Sutro Biopharma's innovative approach and its strategic partnerships, which are expected to contribute to the company's growth and value in the biopharmaceutical industry.
In other recent news, Sutro Biopharma has made significant strides in its clinical trials and financial performance. BofA Securities and H.C. Wainwright have maintained their Buy ratings, reflecting confidence in Sutro's clinical development strategy. Truist Securities adjusted the company's stock price target to $15.00, while maintaining a Buy rating. Piper Sandler confirmed its Overweight rating with a consistent price target of $11.00, noting the company's strong financial footing.
Sutro Biopharma has initiated a global Phase 2 clinical trial for its drug luveltamab tazevibulin, targeting non-small cell lung cancer patients. The company has also reported a promising 56% objective response rate in its Phase I/II trial for its drug luvelta, used in treating late-stage ovarian cancer.
Sutro Biopharma is also progressing with the enrollment of approximately 516 women for further trials and is actively enrolling patients for a Phase II study targeting non-small cell lung cancer.
TD Cowen reiterated its Buy rating, reflecting optimism about luvelta, particularly the 56% ORR observed at the recommended phase 2 dose. The company is preparing to initiate the registrational REFRaME-P1 trial for pediatric acute myeloid leukemia.
Sutro Biopharma announced a strong financial position, having $376 million in cash at the end of the second quarter of 2024, alongside approximately $77 million in shares of PCVX. These are recent developments for Sutro Biopharma as it seeks to advance its drug candidates through the regulatory process.
InvestingPro Insights
Recent InvestingPro data provides additional context to Sutro Biopharma's (NASDAQ:STRO) financial position and market performance. Despite the positive outlook from Piper Sandler, the company's stock has faced challenges, with a 28.2% decline over the past month and an 8.31% drop in the last week. This aligns with the InvestingPro Tip that suggests the stock "has taken a big hit over the last week" and is currently in "oversold territory" according to its RSI.
Financially, Sutro's revenue growth is impressive, with a 197.83% increase in the last twelve months as of Q2 2024. However, the company is not yet profitable, with a negative gross profit margin of -28.92% and an operating income margin of -62.67%. This reflects the InvestingPro Tip indicating that Sutro "suffers from weak gross profit margins" and is "quickly burning through cash."
On a positive note, Sutro "holds more cash than debt on its balance sheet," which could provide financial flexibility as it advances its pipeline and pursues strategic partnerships. This strong liquidity position is crucial for biotechnology companies in the development stage.
For investors seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for Sutro Biopharma, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.